Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-ornithine L-aspartate (LOLA) is a stable salt of the natural amino acids L-ornithine and L-aspartic acid, primarily used in the treatment of hepatic encephalopathy (HE) and other hyperammonemic states associated with liver disease. LOLA acts as a metabolic substrate that enhances ammonia detoxification through two primary pathways: the urea cycle in periportal hepatocytes and glutamine synthesis in perivenous hepatocytes and skeletal muscle. By providing ornithine and aspartate, the drug facilitates the conversion of toxic ammonia into urea and glutamine, thereby reducing systemic ammonia levels and improving neurocognitive function in patients with liver cirrhosis. It is available in both oral (granules) and intravenous formulations and is being investigated for broader applications in liver disorders such as non-alcoholic fatty liver disease (NAFLD).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on l-ornithine l-aspartate (Merz).